Asia Pacific Motion Sickness Treatment Market

Asia Pacific Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

Report Id: KBV-15122 Publication Date: April-2023 Number of Pages: 87
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Motion Sickness Treatment Market, by Drug Class
1.4.2 Asia Pacific Motion Sickness Treatment Market, by Route of Administration
1.4.3 Asia Pacific Motion Sickness Treatment Market, by Distribution Channel
1.4.4 Asia Pacific Motion Sickness Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Asia Pacific Motion Sickness Treatment Market by Drug Class
3.1 Asia Pacific Antihistamines Market by Country
3.2 Asia Pacific Anticholinergics Market by Country
3.3 Asia Pacific Others Market by Country

Chapter 4. Asia Pacific Motion Sickness Treatment Market by Route of Administration
4.1 Asia Pacific Oral Market by Country
4.2 Asia Pacific Others Market by Country

Chapter 5. Asia Pacific Motion Sickness Treatment Market by Distribution Channel
5.1 Asia Pacific Drug Store & Retail Pharmacies Market by Country
5.2 Asia Pacific Hospital Pharmacies Market by Country
5.3 Asia Pacific Online Pharmacies Market by Country

Chapter 6. Asia Pacific Motion Sickness Treatment Market by Country
6.1 China Motion Sickness Treatment Market
6.1.1 China Motion Sickness Treatment Market by Drug Class
6.1.2 China Motion Sickness Treatment Market by Route of Administration
6.1.3 China Motion Sickness Treatment Market by Distribution Channel
6.2 Japan Motion Sickness Treatment Market
6.2.1 Japan Motion Sickness Treatment Market by Drug Class
6.2.2 Japan Motion Sickness Treatment Market by Route of Administration
6.2.3 Japan Motion Sickness Treatment Market by Distribution Channel
6.3 India Motion Sickness Treatment Market
6.3.1 India Motion Sickness Treatment Market by Drug Class
6.3.2 India Motion Sickness Treatment Market by Route of Administration
6.3.3 India Motion Sickness Treatment Market by Distribution Channel
6.4 South Korea Motion Sickness Treatment Market
6.4.1 South Korea Motion Sickness Treatment Market by Drug Class
6.4.2 South Korea Motion Sickness Treatment Market by Route of Administration
6.4.3 South Korea Motion Sickness Treatment Market by Distribution Channel
6.5 Singapore Motion Sickness Treatment Market
6.5.1 Singapore Motion Sickness Treatment Market by Drug Class
6.5.2 Singapore Motion Sickness Treatment Market by Route of Administration
6.5.3 Singapore Motion Sickness Treatment Market by Distribution Channel
6.6 Malaysia Motion Sickness Treatment Market
6.6.1 Malaysia Motion Sickness Treatment Market by Drug Class
6.6.2 Malaysia Motion Sickness Treatment Market by Route of Administration
6.6.3 Malaysia Motion Sickness Treatment Market by Distribution Channel
6.7 Rest of Asia Pacific Motion Sickness Treatment Market
6.7.1 Rest of Asia Pacific Motion Sickness Treatment Market by Drug Class
6.7.2 Rest of Asia Pacific Motion Sickness Treatment Market by Route of Administration
6.7.3 Rest of Asia Pacific Motion Sickness Treatment Market by Distribution Channel

Chapter 7. Company Profiles
7.1 Viatris, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental Analysis
7.1.4 Research & Development Expense
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Amneal Pharmaceuticals, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Baxter International, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental Analysis
7.4.4 Research & Development Expense
7.5 Novartis AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Abbott Laboratories
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 Sun Pharmaceutical Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Zydus Lifesciences Ltd.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 Prestige Consumer Healthcare, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.10. WellSpring Pharmaceutical Corporation (Avista Capital Partners)
7.10.1 Company Overview
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo